Danaher (DHR) Stock
Diversified science company for life sciences and diagnostics. Here's the price, business snapshot, and what's worth knowing about Danaher in August 2026.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It’s Moving
Danaher’s earnings beat and firmer outlook are keeping upside expectations alive
- Second-quarter results beat expectations, with adjusted EPS of $1.94 and revenue of $6.26 billion, reinforcing the view that Danaher’s core businesses are still expanding despite a mixed industrial backdrop.
- Management raised full-year EPS guidance to $8.45-$8.60, signaling confidence in margin resilience and giving investors a clearer path to stronger profit growth into the second half of the year.
- Analysts remain broadly constructive, with a consensus leaning positive as they point to improving earnings quality, solid free cash flow, and a steadier growth outlook after earlier biotech-related weakness.
Danaher’s earnings beat and firmer outlook are keeping upside expectations alive
- Second-quarter results beat expectations, with adjusted EPS of $1.94 and revenue of $6.26 billion, reinforcing the view that Danaher’s core businesses are still expanding despite a mixed industrial backdrop.
- Management raised full-year EPS guidance to $8.45-$8.60, signaling confidence in margin resilience and giving investors a clearer path to stronger profit growth into the second half of the year.
- Analysts remain broadly constructive, with a consensus leaning positive as they point to improving earnings quality, solid free cash flow, and a steadier growth outlook after earlier biotech-related weakness.
Sixth Month Growth Performance
next-earnings-question
Danaher’s next earnings date is expected on October 20, 2026, based on its historical reporting cadence. The report will cover Q3 2026. If the company changes its schedule, the exact date could shift slightly, but mid-to-late October is the typical timing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher's stock, expecting its price to rise significantly to $258.7.
Financial Health
Danaher is performing well with strong revenues and cash flow, indicating solid financial stability.
Dividend
Danaher's dividend yield of 0.76% is low, indicating limited income potential for investors. If you invested $1000 you would be paid $7.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
